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Background and purpose: Chemokines play a critical role in the pathogenesis of asthma and facilitate the recruitment of
inflammatory cells in the airways. Evidence now suggests that airway smooth muscle (ASM) may serve as a source of
chemokines in inflamed airways. Although vitamin D has potent anti-inflammatory properties in vitro in some cell types, its
effects on ASM cells remain unclear. Here, we investigated whether 1a, 25-dihydroxy vitamin D3 (calcitriol) modulated
chemokine production in ASM.
Experimental approach: Human ASM cell cultures were derived from tracheal samples taken during surgery. ASM cells were
treated with tumour necrosis factor alpha (TNFa) and/or interferon gamma (IFNg) for 24h in the presence of calcitriol and/or
the glucocorticoid fluticasone added 2h before. RANTES (regulated upon activation, normal T-cell expressed and secreted),
interferon-inducible protein 10 (IP-10) and fractalkine (FKN) levels in cell supernatants were measured by ELISA.
Key results: In TNFa-treated cells, calcitriol inhibited RANTES and IP-10 secretion in a concentration-dependent manner. FKN
levels were negligible. In TNFa/IFNg-treated cells, whereas fluticasone or calcitriol alone partially inhibited RANTES secretion
(by 38 and 20%, respectively), the combination of both drugs additively inhibited RANTES secretion (by 60%). No effect was
observed on IP-10 secretion. Whereas fluticasone enhanced FKN secretion (by 50%), calcitriol significantly decreased FKN
levels (by 50%). Interestingly, calcitriol blocked the stimulatory effect of fluticasone on FKN secretion, which was inhibited by
60% with the combination of calcitriol and fluticasone.
Conclusions and implications: These findings suggest that vitamin D uniquely modulates human ASM expression of
chemokines and may exert some beneficial effects in the treatment of steroid-resistant patients with asthma.
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Introduction
Vitamin D, a secosteroid hormone synthesized in the skin or
derived from nutritional sources, serves a variety of functions
that include immunomodulation, bone homoeostasis and
wound healing (Holick, 1994; van Etten and Mathieu, 2005;
Lips, 2006). Deficiency in vitamin D has been linked to
autoimmune diseases, carcinogenesis, and importantly,
different inflammatory diseases (Mathieu and Badenhoop,
2005; Munger et al., 2006; Mullin and Dobs, 2007; Schwartz
and Skinner, 2007). Therapeutic approaches using active
vitamin D in chronic inflammatory skin diseases, such as
psoriasis, show that treatment of normal human dermal
fibroblasts and keratinocytes inhibits chemokine production
(Fukuoka et al., 1998a). Others found that vitamin D receptor
(VDR)-deficient mice are more susceptible to inflammatory
bowel disease (Cantorna et al., 2004). The role of vitamin D,
however, in preventing airway inflammatory diseases such as
asthma remains unclear (Black and Scragg, 2005; Wjst, 2006;
Devereux, 2007).
Asthma, a chronic disease with increasing incidence in the
United States, manifests as airway hyper-responsiveness and
inflammation. Asthma prevalence continues to increase
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equator have highest prevalence (Busse and Lemanske,
2001; Litonjua and Weiss, 2007; Moorman et al., 2007; Rudd
and Moorman, 2007). Investigators postulate that the
increase in asthma incidence in industrialized populations
may relate to the longer time spent indoors, decreasing,
therefore, the solar UV-B radiation that penetrates the skin
and converts 7-dehydrocholesterol to active vitamin D
(Holick, 2007; Weiss and Litonjua, 2007). Although analysis
of the data from the third National Health and Nutrition
Examination survey demonstrates a strong relationship
among serum concentrations of vitamin D, forced expiratory
vital capacity and forced expiratory volume in 1second
(Black and Scragg, 2005), the serum concentration of
vitamin D in patients suffering from asthma compared with
normal controls has not yet been investigated. Other studies,
however, suggested that vitamin D deficiency may increase
the incidence of asthma. Two prospective cohort studies
showed an inverse association between intake of vitamin D
and childhood wheezing (Camargo et al., 2007; Devereux
et al., 2007). A study on a founder population in Quebec and
another using a childhood asthma management network
suggest associations among VDR polymorphisms and
asthma (Poon et al., 2004; Raby et al., 2004). Accordingly,
Topilski et al. (2004) observed a reduction in interleukin (IL)-
4 levels and eosinophil counts in the bronchoalveolar lavage
in subjects with asthma after vitamin D administration.
However, the effect of vitamin D on the immunomodulatory
role of airway structural cells in asthma remains unknown.
Although bronchomotor tone is primarily regulated by
airway smooth muscle (ASM) and profoundly contributes to
the asthmatic diathesis, compelling evidence now suggests
that ASM cells also modulate airway inflammation and
remodelling in asthma by secreting a variety of inflamma-
tory proteins, such as cytokines and chemokines, and by
expressing cell adhesion and Toll-like receptor molecules (see
Tliba et al., 2008a). Some studies have investigated the effect
of vitamin D on ASM functions. Accordingly, vitamin D
alters expression of a variety of genes as determined by
microarray (Bosse et al., 2007). Another showed that vitamin
D treatment inhibited ASM growth impeding ASM cell cycle
traversal (Song et al., 2007). The effect of vitamin D,
however, in modulating ASM synthetic function has not
been investigated. In this study, we examined the anti-
inflammatory effects of vitamin D in comparison with
glucocorticoids (GCs) on cytokine-induced chemokine pro-
duction in human ASM cells.
Materials and methods
ASM cell culture and characterization
Human trachea was obtained from lung transplant donors in
accordance with procedures approved by the University of
Pennsylvania Committee on Studies Involving Human
Beings. Human ASM cell culture was performed as described
previously (Panettieri et al., 1989). A segment of trachea just
proximal to the carina was removed under sterile conditions,
and the trachealis muscle was isolated. The muscle was then
centrifuged and resuspended in 10mL of buffer containing
0.2mM CaCl2, 640UmL
 1 collagenase, 1mgmL
 1 soyabean
trypsin inhibitor and 10UmL
 1 elastase. Enzymatic
dissociation of the tissue was performed for 90min in a
shaking water bath at 371C. The cell suspension was filtered
through 105-mm Nytex mesh, and the filtrate was washed
with equal volumes of cold Ham’s F-12 medium supplemented
with 10% fetal bovine serum (HyClone, Logan, UT, USA).
Aliquots of the cell suspension were plated at a density of
1.0 10
4 cellscm
 2. The cells were cultured in Ham’s F-12
medium supplemented with 10% FBS, 100UmL
 1 penicillin,
0.1mgmL
 1 streptomycin and 2.5mgmL
 1 amphotericin B,
and this was replaced every 72h. Human ASM cells in
subculture during the second through fifth cell passages were
used, as these cells retain native contractile protein expres-
sion as demonstrated by immunocytochemical staining for
smooth muscle actin and myosin.
Measurement of RANTES, IP-10 and FKN secretion by ASM cells
by ELISA
Confluent ASM cells were growth-arrested by incubating the
monolayers in Ham’s F-12 medium with 0.1% bovine serum
albumin for 24h and stimulated with tumour necrosis factor
alpha (TNFa) (10ngmL
 1) and/or interferon gamma (IFNg)
(500IUmL
 1) for 24h. To investigate the effect of vitamin D
and/or a GC on cytokine-induced chemokine secretion, ASM
cells were pretreated with 1a, 25-dihydroxy vitamin D3
(calcitriol) and/or the GC, fluticasone at the indicated doses
for 2h before cytokine treatment. To examine the kinetics
of vitamin D-mediated inhibition of cytokine-induced
chemokine expression, ASM cells were treated with TNFa
(10ngmL
 1) and IFNg (500IUmL
 1) for 24h, and
monolayers were treated with calcitriol (100nM) either 1h
before, simultaneously, or 6, 12 or 18h following cytokine
stimulation. The concentrations of RANTES (regulated upon
activation, normal T-cell expressed and secreted), interferon-
inducible protein 10 (IP-10) and FKN in the culture medium
were determined by ELISA according to the manufacturer’s
instructions using specific Duo Set Kits (R&D Systems,
Minneapolis, MN, USA) (Tliba et al., 2004).
Reverse transcription-PCR analysis
Total RNA was extracted from human ASM cells using
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) as previously
described (Tliba et al., 2006). In preliminary experiments, we
determined, for each primer pair, the melting temperature
and number of amplification cycles necessary to yield the
appropriate hybridization signal. The PCR of 25-hydroxy-
vitamin D-24-hydroxylase (CYP24A1), VDR and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) was performed
using previously published primers (Song et al., 2007).
Statistical analysis
Data points from individual assays represent the mean
values of triplicate measurements. Significant differences
among groups were assessed with analysis of variance
(Bonferroni–Dunn test) or by t-test analysis, with values of
Po0.05 sufficient to reject the null hypothesis for all
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minimum of three different human ASM cell preparations.
Materials and reagents
Tissue culture reagents and primers were obtained from
Invitrogen (Carlsbad, CA, USA). Human recombinant (r)
TNFa and rIFNg were provided by Roche Diagnostics
(Indianapolis, IN, USA). Calcitriol (1a, 25-dihydroxy vitamin
D3) and fluticasone propionate were purchased from Cayman
Chemical (Ann Arbor, MI, USA) and Sigma (St Louis, MO,
USA), respectively.
Results
Human ASM cells express functional VDRs
Reverse transcription-PCR analysis showed that VDRs were
expressed in untreated ASM (Figure 1, top gel). The addition
of calcitriol (100nM) further increased the mRNA expression
level of VDR. When ratios of densitometric levels of mRNA
for VDR (relative to GAPDH mRNA levels) were examined,
calcitriol treatment induced 1.7±0.3-fold increase over
basal. Interestingly, calcitriol profoundly stimulated mRNA
expression of CYP24A1, a direct target gene for VDRs
(Giarratana et al., 2004) (Figure 1, middle gel), suggesting
that primary ASM cells express functional VDRs.
Calcitriol inhibits TNFa-induced RANTES and IP-10 secretion
Human ASM cultures were treated with TNFa (10ngmL
 1)
for 24h, and RANTES, IP-10 and FKN protein levels in culture
media were subsequently measured by ELISA. As shown in
Figure 2, TNFa treatment of ASM cells markedly increased
RANTES and IP-10 but not FKN secretion (data not shown).
To investigate the effect of vitamin D, ASM cells were
pretreated with increasing doses of calcitriol (0.001–100nM)
before addition of TNFa (10ngmL
 1) for 24h. Significant
inhibition of RANTES (35±5%) (Figure 2a) and IP-10
(45±6.2%) (Figure 2c) secretion was observed after pretreat-
ment with low concentrations of calcitriol (0.1nM; Po0.05).
Maximal inhibition of RANTES (61±2.8%) and IP-10
(75±3.1%) was achieved at 100nM of calcitriol (Po0.01).
We next compared vitamin D in terms of its suppressive
VDR
CYP24A1
GAPDH
Calcitriol (nM) 0 100
Figure 1 Effect of calcitriol on vitamin D receptor (VDR) and
25-hydroxyvitamin D-24-hydroxylase (CYP24A1) mRNA expression
in human airway smooth muscle (ASM) cells. Cells were treated for
24h with 100nM of calcitriol. Total mRNA (2mg) was then subjected
to reverse transcription-PCR using VDR (top gel), CYP24A1 (middle
gel) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (lower
gel) primers. PCR products were resolved on a 1% agarose gel and
stained with ethidium bromide. Data are representative of three
different cell lines.
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Figure 2 Calcitriol inhibits tumour necrosis factor alpha (TNFa)-induced secretion of chemokines in airway smooth muscle (ASM) cells.
Cells were stimulated for 24h with TNFa (10ngmL
 1) in the presence or absence of calcitriol (0.001–100nM)( a, c) or fluticasone (Fp)
(0.01–100nM)( b, d) added 2h before. Secretion of RANTES (a, b) and IP-10 (c, d) was analysed as described under Materials and methods.
Values shown are mean±s.e.mean of three separate experiments. *Po0.05 compared with cells treated with TNFa alone; **Po0.01 compared
with cells treated with TNFa alone; ***Po0.001 compared with cells treated with TNFa alone.
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significant inhibition of RANTES (21±2.3%) (Figure 2b)
was achieved with 0.01nM of fluticasone (Po0.05), 0.1nM of
fluticasone was required to significantly inhibit IP-10 secre-
tion (43±5.5%) (Figure 2d) (Po0.05). Interestingly, the
effect of fluticasone on chemokine production was greater
than that of calcitriol. Whereas calcitriol failed to abolish
RANTES (61±2.8% inhibition) (Figure 2a) and IP-10
(75±3.1% inhibition) (Figure 2c) secretion, a complete
inhibition of RANTES (Figure 2b) and IP-10 (Figure 2d) was
achieved at 10nM of fluticasone (Po0.001). These data
suggest that the mechanisms regulating TNFa-induced
RANTES and IP-10 secretions may be more sensitive to GC
than to vitamin D.
Calcitriol inhibits expression of chemokines despite steroid
resistance
We and others recently showed that the combination of
TNFa with IFNg alters the ability of GCs to inhibit the
expression of different pro-asthmatic genes (Tliba et al.,
2006, 2008b; Tliba and Amrani, 2008). We next examined
the effect of vitamin D on the expression of chemokines in
ASM cells treated with TNFa and IFNg that render ASM
steroid resistant. ASM cells were treated with TNFa
(10ngmL
 1) and IFNg (500IUmL
 1) for 24h and increasing
doses of either fluticasone (0.001–100nM) or calcitriol
(0.001–100nM) were added 2h before. As shown in Figure 3,
TNFa and IFNg dramatically increased RANTES (2.6±0.25-
fold increase compared with that obtained in cells treated
with TNFa alone) (Figure 3a) and IP-10 levels (46±3.1-fold
increase compared with that obtained in cells treated with
TNFa alone) (Figure 3c). Whereas TNFa alone has little effect
(data not shown), only the combination of TNFa and IFNg
significantly increased FKN secretion levels (Figure 3e).
No effect of calcitriol or GC was observed on IP-10
production in TNFa/IFNg-treated ASM cells at all doses
tested (0.001–100nM) (Figures 3c and d). Only when used
at the highest dose (100nM), calcitriol and fluticasone
partially inhibited RANTES secretion in TNFa/IFNg-treated
cells (Figures 3a and b). Although fluticasone completely
inhibited RANTES secretion in cells treated with TNFa alone
(Figure 2b), this steroid only partially inhibited RANTES
secretion in TNFa/IFNg-treated cells (40±4.1%; Po0.05)
(Figure 3a). Calcitriol inhibition of RANTES secretion was
also less effective in TNFa/IFNg-treated cells (24±5.6%;
Po0.05) (Figure 3b) compared with TNFa-treated cells
(61±2.8%; Po0.01; Figure 2a). As shown in Figure 3e,
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Figure 3 Calcitriol differentially regulates chemokine secretion in airway smooth muscle (ASM) cells treated with tumour necrosis factor alpha
(TNFa) and interferon gamma (IFNg) combination. Cells were stimulated for 24h with TNFa (10ngmL
 1) and IFNg (500IUmL
 1) in the
presence or absence of fluticasone (Fp) (0.001–100nM)( a, c, e) or calcitriol (0.001–100nM)( b, d, f) added 2h before. Secretion of RANTES
(a, b), IP-10 (c, d) and fractalkine (FKN) (e, f) was analysed as described under Materials and methods. Values shown are mean±s.e.mean of three
separate experiments. *Po0.05 compared with cells treated with TNFa and IFNg;* * Po0.01 compared with cells treated with TNFa and IFNg.
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dependent manner in TNFa/IFNg-treated ASM cells. At low
doses (0.001–1nM), fluticasone slightly enhanced FKN
secretion. Significant increases were observed only at higher
doses of fluticasone (48±2.7% with 100nM of fluticasone).
In contrast, calcitriol inhibited FKN release in a concentra-
tion-dependent manner (Figure 3f). When used at 0.1nM,
calcitriol significantly inhibited FKN production (29±3.6%;
Po0.05). Maximal inhibition of cytokine-induced FKN
expression was achieved with 10nM of calcitriol (55±2.5%;
Po0.01).
Time course analysis of the inhibitory effect of vitamin D on
chemokine production in steroid-resistant conditions
We next investigated the kinetics of vitamin D-mediated
inhibition of cytokine-induced RANTES (Figure 3b) and FKN
(Figure 3f) expression in ASM cells. The inhibitory effect of
calcitriol on RANTES (Figure 4a) and FKN (Figure 4b) was
apparent when added 1h before, simultaneously and 6h
following the addition of cytokines. However, when calci-
triol was added into the culture at 12 or 18h after cytokine
stimulation, there was no effect (Figure 4). Collectively, these
data suggest that 18h of cell treatment with vitamin D is
required to inhibit cytokine-induced RANTES and FKN
secretions.
The combination of vitamin D and GC additively inhibits
chemokine secretion
We next examined whether the combination of vitamin D
and GC could additively reduce RANTES and FKN produc-
tion in TNFa/IFNg-treated ASM cells. As shown before
(Figures 3a and b), pretreatment of the cells with either
100nM of calcitriol or 100nM of fluticasone differentially
inhibited TNFa/IFNg-induced RANTES release with flutica-
sone being more effective (21±2.3 and 39±3.5%, respec-
tively; Po0.05) (Figure 5a). Interestingly, the combination of
calcitriol and fluticasone additively inhibited cytokine-
induced RANTES (62±3.2%; Po0.01).
Conversely, calcitriol and fluticasone either alone or in
combination had little effect on IP-10 secretion in TNFa/
IFNg-treated cells (Figure 5b). Moreover, as shown before
(Figures 3e and f), although pretreatment of the cells with
100nM of fluticasone enhanced FKN production (51±1.8%;
Po0.05), pretreatment with 100nM of calcitriol reduced FKN
production in TNFa/IFNg-treated ASM cells (51±1.2%;
Po0.01) (Figure 5c). Interestingly, calcitriol also inhibited
the fluticasone-enhancing effect on FKN production
(61±2.2% compared with fluticasone/TNFa/IFNg-treated
cells; Po0.001) (Figure 5c).
Discussion
We explored the anti-inflammatory effect of vitamin D in
terms of chemokine secretion from human ASM cells.
Vitamin D effectively inhibited chemokine secretion in
ASM cells treated with TNFa alone. In steroid-resistant
conditions, however, vitamin D differentially modulated
chemokine gene expression. Surprisingly, vitamin D signifi-
cantly reduced the expression of a steroid-resistant gene,
FKN. To our knowledge, this is the first report showing that
vitamin D may inhibit the expression of steroid-resistant
genes in any cell type.
Effects of vitamin D are in part mediated via the
stimulation of VDRs (Carlberg and Seuter, 2007). Previous
studies in bronchial ASM suggest that vitamin D analogues
profoundly increase the expression of CYP24A1 (241-fold)
and of VDRs (1.6-fold) levels (Bosse et al., 2007). We also
showed that vitamin D increases both the expression of
VDRs (1.7-fold) and CYP24A1 in tracheal ASM. These
findings demonstrate the ability of ASM, whether bronchial
or tracheal, to respond to vitamin D. Most of the effects of
vitamin D are to modulate cell function by activating VDRs
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Figure 4 Time course analysis of the inhibitory effects of calcitriol on chemokine secretion in tumour necrosis factor alpha (TNFa)/interferon
gamma (IFNg)-treated airway smooth muscle (ASM) cells. Cells were stimulated for 24h with TNFa (10ngmL
 1) and IFNg (500IUmL
 1), and
100nM of calcitriol was added either 1h before, simultaneously, or 6, 12 and 18h after cytokine treatment. Secretion of RANTES (a) and
fractalkine (FKN) (b) was analysed as described under Materials and methods. Values shown are mean±s.e.mean of three separate
experiments. *Po0.05 compared with cells treated with TNFa/IFNg;* * Po0.01 compared with cells treated with TNFa and IFNg.
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D-responsive genes (see van Etten and Mathieu, 2005).
Beside this genomic mechanism of action, vitamin D may
also act through rapid non-genomic effects (see Marcin-
kowska, 2001). In agreement with previous studies in
immune cells (Yu et al., 1995; Xing et al., 2002), our time
course analysis revealed that vitamin D exerted its inhibitory
effects on chemokine production through genomic mecha-
nisms that required a minimum of 18h of exposure
(Figure 4). These findings corroborate with those of others
who have shown that extended exposure of vitamin D also
modulates the expression of ASM contractile genes (Bosse
et al., 2007) and proliferation (Song et al., 2007). Our study
extends the knowledge of the effects of vitamin D in
modulating the biosynthetic functions of ASM cells.
There is evidence that ASM may serve as a source of
chemokines in allergen-induced airway inflammation that
ultimately recruits and retains inflammatory cells that could
amplify pro-inflammatory markers (see Tliba et al., 2008a).
Consequently, controlling the expression of chemokines by
ASM cells may provide unique therapeutic targets to decrease
cell migration/infiltration, and ultimately reverse either
airway remodelling or airway inflammation. RANTES is a
chemokine that attracts monocytes, eosinophils and T cells
during inflammation and immune response (Schall et al.,
1990). Interestingly, immunohistochemical and in situ
hybridization studies revealed that RANTES is expressed in
smooth muscle bundles of bronchial biopsies in subjects
with asthma (Fahy et al., 1997). We and others showed that
RANTES expression is increased in vitro following TNFa
treatment (see Tliba et al., 2008a). In a variety of cell lines,
vitamin D differentially modulates chemokine expression
(Fukuoka et al., 1998a,b; Xing et al., 2002; Griffin et al., 2004;
Equils et al., 2006). In murine dendritic cells, vitamin D
significantly inhibits RANTES expression, whereas it also
enhances MIP-1a MIP-1b and MCP-1 expression (Xing et al.,
2002; Griffin et al., 2004). In human endothelial cells,
vitamin D abolishes lipopolysaccharide-induced RANTES
secretion and modestly attenuates IL-8 secretion (Equils
et al., 2006). In human dermal fibroblasts and epidermal
keratinocytes, vitamin D inhibits both RANTES and IL-8
secretion (Fukuoka et al., 1998a,b). In agreement with the
latter studies, we showed that vitamin D inhibited TNFa-
induced RANTES release in ASM cells in a concentration-
dependent manner. Importantly, the inhibition of RANTES
expression by vitamin D observed in the current study was of
particular interest as neutralizing RANTES expression in
murine models of allergen-induced airway hyper-responsive-
ness dramatically reduces airway mucus secretion as well as
leukocyte migration (Chvatchko et al., 2003).
IP-10 (CXCL10) is a potent chemokine for activated Tcells,
NK cells and mast cells (Luster et al., 1985). Immuno-
histochemical study showed that IP-10 was preferentially
expressed by ASM obtained from subjects with asthma
(Brightling et al., 2005). IP-10 neutralization also inhibits
mast cell migration towards asthmatic ASM cells (Brightling
et al., 2005). We show that IP-10 expression was also
increased following ASM treatment with TNFa (Figure 2).
The modulatory effect of vitamin D on IP-10 expression in
immune cells, however, remains controversial. For instance,
vitamin D enhanced IP-10 production in peripheral blood
monocytes and Langerhans cells (Vidal et al., 2002; Fujita
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Figure 5 Effects of the combination of fluticasone with calcitriol on chemokine secretion in tumour necrosis factor alpha (TNFa)/interferon
gamma (IFNg)-treated airway smooth muscle (ASM) cells. Cells were pretreated with calcitriol (100nM), fluticasone (Fp) (100nM)o ra
combination of both agents for 2h before incubation with TNFa (10ngmL
 1) and IFNg (500IUmL
 1) for an additional 24h. Secretion of
RANTES (a), IP-10 (b) and fractalkine (FKN) (c) was analysed as described under Materials and methods. Values shown are mean±s.e.mean of
three separate experiments. *Po0.05 compared with cells treated with TNFa and IFNg;* * Po0.01 compared with cells treated with TNFa and
IFNg.
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observations in other cell types including ASM cells.
A number of studies performed either in murine bone
marrow-derived macrophages or in pancreatic islets
cells have consistently shown decreased IP-10 expression
after vitamin D treatment (Gysemans et al., 2005; Helming
et al., 2005). Concordantly, we showed that treatment of
ASM cells with vitamin D significantly reduced TNFa-
induced IP-10 secretion. These conflicting results may be
explained by different experimental design using diverse
exposure periods to vitamin D (ranging from 18h to 6 days)
and a variety of cell types whose sensitivity to inflammatory
cytokines and/or vitamin D responses may vary. The effect of
vitamin D on IP-10 expression may also depend on the
differentiation status of the cells as suggested by Helming
et al. (2005) in myeloid precursors/monocytes and mature
macrophages. Further studies will be necessary to address the
differential cell-specific effects of vitamin D on IP-10 gene
expression.
Inhaled corticosteroids are the most effective agents
available for symptomatic control and improvement of
pulmonary function in asthma (Busse and Lemanske,
2001). Although most patients with asthma achieve control
with inhaled steroids, there remains about 15% of patients
who are steroid-insensitive (Adcock and Lane, 2003). Despite
high doses of steroids, the therapeutic approach remains
ineffective at restoring lung function (Wenzel, 2005). We and
others recently showed that treatment of ASM cells with the
combination of TNFa and IFNg impairs the ability of steroids
to inhibit the expression of different pro-asthmatic genes
(Sukkar et al., 2004, 2006; Tliba et al., 2006, 2008b) by
mechanisms, in part, involving the upregulation of the
b isoform of the GC receptor and the reduction of GC
receptor binding to GC-responsive elements of target DNA
(Tliba et al., 2006). In contrast to the broad inhibitory effect
of vitamin D on chemokine expression in steroid-sensitive
cells (TNFa-treated ASM cells), we found that vitamin D
differentially regulated chemokine expression in steroid-
resistant cells (TNFa/IFNg-treated ASM cells). Although
calcitriol had little effect on IP-10 secretion and only slightly
reduced RANTES secretion, calcitriol inhibited FKN
expression (Figure 3f). To our knowledge, our study is the
first to report that vitamin D inhibits FKN expression. Of
note, no FKN release was observed when ASM cells were
treated with TNFa alone. FKN is a CX3C chemokine that
mediates mast cell recruitment to the ASM in asthmatics
(El-Shazly et al., 2006). This chemokine is a structurally
unique protein in which a chemokine-like domain is located
atop a mucin stalk connected to a transmembrane domain.
A soluble form of FKN is generated by proteolytic cleavage
of the full-length molecule at the membrane proximal
site (Tsou et al., 2001). Although the membrane-bound form
of FKN acts as an adhesion molecule (Fujimoto et al., 2001),
the soluble form of FKN has chemotactic functions
(Haskell et al., 2000). In the present study, only the soluble
form of FKN was investigated. Interestingly, elevated levels of
soluble FKN have been demonstrated in asthmatics before
and after allergen challenge (Rimaniol et al., 2003).
Importantly, the secretion of FKN from ASM is resistant to
steroid treatment, and steroid actually increases FKN
production (Figure 3e and Sukkar et al., 2004). The inhibition
of FKN mRNA transcription (data not shown) by vitamin D
suggests that vitamin D was downregulating both soluble
and membrane-bound forms of FKN and was not simply
altering the balance of membrane-bound FKN to secreted
FKN. Thus, the ability of vitamin D to inhibit the transcrip-
tional induction of FKN (Figure 3f and data not shown), a
steroid-resistant chemokine in ASM cells, is of specific
interest and may have therapeutic benefit in steroid-resistant
states. Xystrakis et al. (2006) have already shown that
administration of vitamin D to steroid-resistant asthmatic
patients enhanced subsequent responsiveness of T CD4
þ
regulatory cells to dexamethasone. Taken together, vitamin
D modulates the expression of steroid-resistant genes in
airway structural cells and restores steroid responsiveness
in immune cells (Xystrakis et al., 2006), suggesting that
vitamin D may hold promise in the treatment of patients
with severe asthma.
Because of the efficiency of GCs in asthma, the develop-
ment of alternative anti-inflammatory agents has been
challenging (Barnes and Hansel, 2004). The possibility of
combining GCs with other agents may improve the
therapeutic index of either drug used alone. In steroid-
resistant cells and in combination with steroids, vitamin D
showed interesting additive effects in inhibiting RANTES
secretion (Figure 5). Similar findings were also reported in
dendritic cells where vitamin D and GC additively inhibited
RANTES mRNA expression (Xing et al., 2002). A vitamin D
analogue, calcipotriol, is used in conjunction with steroids
to treat psoriasis, a common chronic inflammatory skin
disease characterized by hyper-proliferation and defective
differentiation of epidermal keratinocytes (Menter and
Griffiths, 2007; Nickoloff et al., 2007). Evidence also suggests
that vitamin D administered with high doses of GCs could be
useful as prophylaxis against GC-induced osteoporosis
(Compston, 2007; Papierska and Rabijewski, 2007). Taking
all these findings together, we propose that vitamin D may
be useful for asthma control as a potential therapeutic
adjunct with steroids.
In conclusion, we demonstrate that vitamin D exerts anti-
inflammatory activity in ASM relevant to the pathogenesis of
chronic inflammatory airway disease, such as asthma and
chronic obstructive pulmonary disease. These findings
support a role of vitamin D as an anti-inflammatory agent.
Our findings open a new area of investigation, namely, to
determine the molecular mechanisms by which vitamin D
modulates the transcriptional regulation of pro-inflamma-
tory genes in airway structural cells.
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